DNA X Inc. amended its charter to authorize up to 1.35 million shares of Series B convertible preferred stock. This issuance authorizes the company to raise capital, potentially providing growth funding and equity benefits to investors.
DNA X Inc. amended its charter to authorize up to 1.35 million shares of Series B convertible preferred stock. This issuance authorizes the company to raise capital, potentially providing growth funding and equity benefits to investors.